Petros Pharmaceuticals, Inc.

OTCPK:PTPI Stock Report

Market Cap: US$257.6k

Petros Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Petros Pharmaceuticals's earnings have been declining at an average annual rate of -28.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 59.5% per year.

Key information

-28.29%

Earnings growth rate

42.91%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate-59.51%
Return on equity-456.83%
Net Marginn/a
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Analysis Article • Nov 13

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...
Seeking Alpha • Aug 15

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Petros Pharmaceuticals press release (NASDAQ:PTPI): Q2 GAAP EPS of -$0.10. Revenue of $6.6M (+0.9% Y/Y).
Seeking Alpha • Jul 28

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Private investment group Henry Crown and Company (HCC) will acquire men's health firm Petros Pharmaceuticals (NASDAQ:PTPI) for $3.25 per share in an all-cash transaction for a total equity value of about $67.2M, the companies said on Thursday. The deal value of $3.25 per share represents a 306.25% premium to PTPI's last closing price of $0.80. PTPI shares zoomed on the announcement, more than tripling in value to $2.63. As per the deal, CVF LLC, an affiliate managing HCC's healthcare investments, will acquire all the outstanding shares of PTPI, which will become a privately-owned company at the close of the transaction. PTPI's board has unanimously approved the merger. HCC expects to finance the deal with existing cash on hand. The companies expect the merger to close by early 2023. The merger also includes the acquisition of PTPI's assets including erectile dysfunction (ED) drug Stendra, a treatment candidate for Peyronie's disease called H100 and a line of medical devices for the treatment of ED.
Seeking Alpha • Dec 07

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Petros Pharmaceuticals is developing complementary men’s health therapeutics. The Company’s target lead indications are erectile dysfunction and Peyronie’s disease. Petros recently announced a $10 million public offering of its common stock for $3 per share.

Revenue & Expenses Breakdown

How Petros Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:PTPI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-1730
31 Mar 260-4140
31 Dec 250-5050
30 Sep 250-5250
30 Jun 250-5450
31 Mar 250-1850
31 Dec 240-1350
30 Sep 240-1571
30 Jun 241-1781
31 Mar 243-1892
31 Dec 236-1492
30 Sep 237-1492
30 Jun 234-2292
31 Mar 236-21102
31 Dec 226-20122
30 Sep 224-24133
30 Jun 228-12152
31 Mar 226-12162
31 Dec 218-9162
30 Sep 2112-6151
30 Jun 2113-8151
31 Mar 2112-11150
31 Dec 2010-21160
30 Sep 209-24160
30 Jun 2010-29190
31 Mar 2012-32200
31 Dec 1916-33200
31 Dec 1814-32110

Quality Earnings: PTPI is currently unprofitable.

Growing Profit Margin: PTPI is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PTPI is unprofitable, and losses have increased over the past 5 years at a rate of 28.3% per year.

Accelerating Growth: Unable to compare PTPI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTPI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).

Return on Equity

High ROE: PTPI has a negative Return on Equity (-456.83%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/18 09:13
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Petros Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nazibur RahmanMaxim Group